Synergistic Activity of Colistin and Rifampin Combination against Multidrug-Resistant Acinetobacter baumannii in an In Vitro Pharmacokinetic/Pharmacodynamic Model
Open Access
- 1 August 2013
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 57 (8) , 3738-3745
Abstract
Combination therapy may be required for multidrug-resistant (MDR) Acinetobacter baumannii . This study systematically investigated bacterial killing and emergence of colistin resistance with colistin and rifampin combinations against MDR A. baumannii . Studies were conducted over 72 h in an in vitro pharmacokinetic (PK)/pharmacodynamic (PD) model at inocula of ∼10 6 and ∼10 8 CFU/ml using two MDR clinical isolates of A. baumannii , FADDI-AB030 (colistin susceptible) and FADDI-AB156 (colistin resistant). Three combination regimens achieving clinically relevant concentrations (constant colistin concentration of 0.5, 2, or 5 mg/liter and a rifampin maximum concentration [ C max ] of 5 mg/liter every 24 hours; half-life, 3 h) were investigated. Microbiological response was measured by serial bacterial counts. Population analysis profiles assessed emergence of colistin resistance. Against both isolates, combinations resulted in substantially greater killing at the low inoculum; combinations containing 2 and 5 mg/liter colistin increased killing at the high inoculum. Combinations were additive or synergistic at 6, 24, 48, and 72 h with all colistin concentrations against FADDI-AB030 and FADDI-AB156 in, respectively, 8 and 11 of 12 cases (i.e., all 3 combinations) at the 10 6 -CFU/ml inoculum and 8 and 7 of 8 cases with the 2- and 5-mg/liter colistin regimens at the 10 8 -CFU/ml inoculum. For FADDI-AB156, killing by the combination was ∼2.5 to 7.5 and ∼2.5 to 5 log 10 CFU/ml greater at the low inoculum (all colistin concentrations) and high inoculum (2 and 5 mg/liter colistin), respectively. Emergence of colistin-resistant subpopulations was completely suppressed in the colistin-susceptible isolate with all combinations at both inocula. Our study provides important information for optimizing colistin-rifampin combinations against colistin-susceptible and -resistant MDR A. baumannii .Keywords
This publication has 53 references indexed in Scilit:
- fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection modelsJournal of Antimicrobial Chemotherapy, 2010
- Hospital-Acquired Infections Due to Gram-Negative BacteriaNew England Journal of Medicine, 2010
- Predictors of acute kidney injury associated with intravenous colistin treatmentInternational Journal of Antimicrobial Agents, 2010
- The 10 × ‘20 Initiative: Pursuing a Global Commitment to Develop 10 New Antibacterial Drugs by 2020Clinical Infectious Diseases, 2010
- Nephrotoxicity Associated with Intravenous Colistin (Colistimethate Sodium) Treatment at a Tertiary Care Medical CenterClinical Infectious Diseases, 2009
- Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2009
- Colistin Heteroresistance in Acinetobacter and Its Association with Previous Colistin TherapyAntimicrobial Agents and Chemotherapy, 2008
- Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: A prospective, open-label, uncontrolled studyClinical Therapeutics, 2008
- Heteroresistance to Colistin in Multidrug-Resistant Acinetobacter baumanniiAntimicrobial Agents and Chemotherapy, 2006
- Colistin Methanesulfonate Is an Inactive Prodrug of Colistin against Pseudomonas aeruginosaAntimicrobial Agents and Chemotherapy, 2006